Public Health Seminar - 2026 - Social Participation - Sustainable Development

As demographics shift rapidly toward an aging society, chronic cardio-cerebrovascular conditions and organ degeneration have emerged as primary healthcare challenges, impacting public well-being and placing increasing strain on national healthcare infrastructure. Grounded in a patient-centric corporate mission and actively answering the United Nations Sustainable Development Goals—specifically SDG 3 (Good Health and Well-being) and SDG 17 (Partnerships for the Goals)—TSH Biopharm Co., Ltd. hosted a flagship public welfare health education seminar titled "Safeguarding Health, Embracing a Wholehearted Lifestyle: Clear Vision and Vibrant Living" at the Chang Yung-Fa Foundation International Convention Center in Taipei.

This seminar forged an interdisciplinary alliance uniting leading authorities across neurology, cardiology, and ophthalmology. The sessions covered the spectrum from root-cause prevention and occult microvascular crises to pioneering therapeutic delivery systems—dismantling doctor-patient information asymmetries, elevating public health literacy, and establishing a robust communal defense against chronic illnesses.

In-Depth Insights from Three Medical Specialties: A Comprehensive Healthcare Prescription

Dr. Chien-Lin Chiang, Neurologist at Linkou Chang Gung Memorial Hospital | Dispelling the Asymptomatic Myth and Activating a "Blood Pressure & Lipid Control" Defense for Brain Health

80% of Strokes Are Preventable; Absence of Pain Does Not Mean Absence of Disease:

Dr. Chiang highlighted that stroke remains a leading cause of mortality in Taiwan, yet 70% to 80% of cases are preventable through timely risk factor management. Clinically, many patients experience no overt symptoms prior to a stroke. However, the absence of discomfort does not indicate vascular integrity; chronic, unmanaged "Three Highs" (hypertension, hyperglycemia, hyperlipidemia) often inflicts silent arterial stiffness and progressive endothelial damage over time.

Implementing the "722 Rule" to Build Precise Blood Pressure Monitoring Habits:

Dr. Chiang urged the public to establish disciplined home blood pressure monitoring by adhering to the "722 Rule": measure for 7 consecutive days, 2 times daily (within 1 hour of waking and before bedtime), with 2 readings per session (spaced 1 minute apart to calculate the average).

Medication Adherence as the Ultimate Defense; Stringent LDL-C Targets:

Regarding lipid management, Dr. Chiang emphasized that low-density lipoprotein cholesterol (LDL-C) serves as the primary benchmark, requiring exceptionally strict targets for very-high-risk patients with a history of stroke. If monotherapy with statins fails to reach target levels, physicians may evaluate adding a cholesterol absorption inhibitor (ezetimibe) as combination therapy. Dr. Chiang cautioned patients never to discontinue or reduce medications independently due to minor lab improvements, which risks plaque rupture; furthermore, upon noticing stroke warning signs, immediate recognition of the FAST emergency mnemonic and calling emergency services (119/911) is imperative to seize critical therapeutic windows.

2. Dr. Wen-Cheng Liu, Cardiologist at Tri-Service General Hospital | Demystifying Coronary Microvascular Dysfunction (CMD) and Unmasking Occult Angina Crises

Cardiovascular Disease Affecting Younger Demographics; Heightened Vigilance for Atypical Chest Pain:

Dr. Liu noted that myocardial infarction and sudden cardiac death increasingly affect younger cohorts, making the 40–60 age group a high-risk demographic. Typical angina is often triggered by physical exertion, cold weather, or emotional stress. However, because chest pain can originate from gastroesophageal reflux disease (GERD), musculoskeletal strain, or pulmonary disorders, recurrent, worsening, or first-onset severe chest pain requires prompt clinical evaluation to rule out acute conditions.

Chest Tightness Despite Normal Coronary Angiograms: Understanding CMD:

Patients frequently present with recurrent chest tightness despite clear coronary arteries on cardiac catheterization. This condition often stems from Coronary Microvascular Dysfunction (CMD) or coronary microvascular vasospasms. CMD is particularly prevalent among postmenopausal women and is closely linked to the "Three Highs," obesity, smoking, sleep deprivation, and chronic systemic inflammation.

Innovative Antianginal Mechanisms Offering Personalized Treatment Strategies:

Beyond lifestyle interventions and cardiovascular risk control, Dr. Liu highlighted that novel pharmacotherapies—such as Late Sodium Current Inhibitors (e.g., Ranolazine)—provide modern therapeutic options for chronic angina. This mechanism alleviates myocardial ischemia and enhances microcirculation with minimal perturbation of blood pressure and heart rate, improving functional capacity and quality of life.

3. Dr. Chien-Liang Wu, Director of Ophthalmology at Wan Fang Hospital & Brilliant Eyecare Clinic | Stimulating Endogenous Tear Secretion: Innovative Nasal Spray Therapies for Dry Eye Disease

Dry Eye Disease Beyond Simple Dehydration; Higher Prevalence in Asian Populations:

Dr. Wu pointed out that the prevalence of Dry Eye Disease (DED) is significantly higher across Asian populations compared to Western demographics, with increased vulnerability among women, older adults, and individuals with diabetes or autoimmune conditions such as Sjögren's syndrome. Pathophysiologically, DED represents an imbalance across the three structural layers of the tear film (lipid, aqueous, and mucin layers). It is categorized into aqueous-deficient, evaporative (lipid-deficient), mucin-deficient, and mixed subtypes, which standard artificial tears alone cannot completely resolve.

Overcoming Administration Hurdles with Non-Ocular Therapeutics:

Conventional ophthalmic drops often present adherence barriers for the elderly, individuals with limited hand dexterity, or patients experiencing ocular drop aversion. The medical field has recently introduced an innovative nasal spray formulation (such as Varenicline), supported by clinical evidence showing that approximately 34% of baseline natural tear secretion is mediated via nasal trigeminal stimulation.

Activating Parasympathetic Pathways to Produce Complete Natural Tears:

This non-ocular formulation stimulates the trigeminal nerve within the nasal mucosa, activating the parasympathetic pathway to directly trigger endogenous, full-composition natural tear production. Operating without touching the ocular surface and fully compatible with contact lens wear, this represents the first novel active pharmaceutical ingredient approved for DED in Taiwan in nearly two decades, enhancing patient compliance and therapeutic accessibility.

TSH Biopharm ESG & UN Sustainable Development Goals Alignment

TSH Biopharm embeds sustainability into public health communication, translating medical expertise into verifiable social impact:

Sustainability Dimension	International Framework / Goal	Action Plan & Social Value Creation
Social Responsibility (Social)	SDG 3.4 Reduce premature mortality from non-communicable diseases (NCDs)	Delivered clinical pathology and preventive education on cardio-cerebrovascular conditions (stroke, CMD angina), promoting the "722 Rule" and strict adherence to reduce chronic disease burden on healthcare systems.
Social Responsibility (Social)	SDG 3.8 Universal health coverage & access to healthcare innovations	Introduced breakthrough non-ocular dry eye nasal sprays and novel antianginal agents, elevating public awareness of innovative medical technology and improving patient quality of life.
Partnership (Governance / Social)	SDG 17.17 Encourage effective public, public-private, and civil society partnerships	Collaborated with leading clinicians from tier-one medical centers (Chang Gung, Tri-Service General, Wan Fang) and partnered with professional health media outlets to broaden public health reach.
Ethical Governance (Governance)	GRI 2-29 Stakeholder engagement & dialogue	Conducted on-site "Stakeholder Materiality Surveys" to capture community expectations regarding health promotion and corporate sustainability, informing corporate governance strategies.

Conclusion and Commitments

TSH Biopharm believes corporate value extends beyond supplying high-quality pharmaceuticals to injecting enduring health and sustainability into society. Moving forward, the company will deepen its commitment to "Knowledge Empowerment, Prevention First, and Whole-Person Care," spearheading diverse public health initiatives and partnering with the medical community to safeguard lifelong cardiovascular, cerebrovascular, and vision wellness.

(Source Reference: NOWhealth / TSH Biopharm Health Education Report)

#TSHBiopharm #ESG #SDG3 #SDG17 #PreventiveMedicine #CardiovascularHealth #HealthLiteracy #StakeholderEngagement #CorporateSustainability

Menu